Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases

Front Immunol. 2023 Mar 6:14:1145814. doi: 10.3389/fimmu.2023.1145814. eCollection 2023.

Abstract

Immune cells have been implicated in interstitial lung diseases (ILDs), although their phenotypes and effector mechanisms remain poorly understood. To better understand these cells, we conducted an exploratory mass cytometry analysis of immune cell subsets in bronchoalveolar lavage fluid (BALF) from patients with idiopathic pulmonary fibrosis (IPF), connective-tissue disease (CTD)-related ILD, and sarcoidosis, using two panels including 64 markers. Among myeloid cells, we observed the expansion of CD14+ CD36hi CD84hiCCR2- monocyte populations in IPF. These CD14+ CD36hi CD84hi CCR2- subsets were also increased in ILDs with a progressive phenotype, particularly in a case of acute exacerbation (AEx) of IPF. Analysis of B cells revealed the presence of cells at various stages of differentiation in BALF, with a higher percentage of IgG memory B cells in CTD-ILDs and a trend toward more FCRL5+ B cells. These FCRL5+ B cells were also present in the patient with AEx-IPF and sarcoidosis with advanced lung lesions. Among T cells, we found increased levels of IL-2R+ TIGIT+ LAG3+ CD4+ T cells in IPF, increased levels of CXCR3+ CD226+ CD4+ T cells in sarcoidosis, and increased levels of PD1+ TIGIT+ CD57+ CD8+ T cells in CTD-ILDs. Together, these findings underscore the diverse immunopathogenesis of ILDs.

Keywords: FCRL5; connective-tissue disease-related interstitial lung disease; idiopathic pulmonary fibrosis; mass cytometry (CyTOF); monocyte; sarcoidosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bronchoalveolar Lavage Fluid
  • CD8-Positive T-Lymphocytes / pathology
  • Connective Tissue Diseases*
  • Humans
  • Idiopathic Pulmonary Fibrosis* / pathology
  • Lung Diseases, Interstitial* / pathology
  • Sarcoidosis*
  • Signaling Lymphocytic Activation Molecule Family

Substances

  • CD84 protein, human
  • Signaling Lymphocytic Activation Molecule Family

Grants and funding

This research was supported by the Kakihara Foundation and Boehringer Ingelheim (TY), and the Japan Agency for Medical Research and Development (YF). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.